Prosigna® (PAM50)

Prosigna® is based on the PAM50 genetic panel, which measures the expression of 50 key mutations in breast cancer. The test involves analyzing expression through the direct measurement of RNA extracted from the surgical specimen. The expression results are then integrated, along with tumor size and the number of affected lymph nodes, using an algorithm that returns three pieces of information: 1) Intrinsic subtype of the breast cancer specimen; 2) Patient-specific risk of recurrence (ROR), ranging from 0 to 100 (low, intermediate, or high); 3) Individual calculation of the probability of distant recurrence within a 10-year period. The test is indicated for patients with HER2-positive breast cancer and hormone receptor (ER or PR) positive breast cancer. The sample must be an FFPE surgical specimen or sections from the tumor (please request instructions if sections are required). Exceptionally, and at the discretion of the prescribing physician, biopsy material may be sent. The blocks that are sent are returned to the center of origin once the test is completed.